Product Description
Sodium chloride is an inorganic chloride salt having sodium(1+) as the counterion. It has a role as an emetic and a flame retardant. It is an inorganic chloride and an inorganic sodium salt. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Sodium-chloride)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Intramuscular,Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Norgine
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description

Countries in Clinic: Australia, Austria, Belgium, Brazil, Bulgaria, Chile, China, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Kenya, Latvia, Lithuania, Malawi, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Portugal, Russia, Slovenia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Uganda, United Kingdom, United States, Unknown Location, Zimbabwe
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Abscess|Asthma, Allergic|Ataxia Telangiectasia|Cervical Cancer|Cervical Intraepithelial Neoplasia|Communicable Diseases|Conjunctivitis, Allergic|Dust mite Hypersensitivity|Emphysema|Endometritis|Environmental Hypersensitivity|Esophageal Cancer|HIV Infections|Heart Failure|Inflammation|Influenza, Human|Injuries/wounds Unspecified|Kidney Diseases|Lyme Disease|Meningitis|Non-Small-Cell Lung Cancer|Oophoritis|Ovarian Diseases|Papillomavirus Infections|Peritonitis|Pleural Effusion, Malignant|Pneumonia|Rhinitis, Allergic|Salpingitis|Small Cell Lung Cancer|Squamous Intraepithelial Lesions of the Cervix|Thyroid Eye Disease|Urinary Tract Infections|alpha 1-Antitrypsin Deficiency
Phase 2: Abdominal Pain|Acute Coronary Syndrome|Alzheimer Disease|Anesthesia Related|Atrial Fibrillation|Bronchopulmonary Dysplasia|CADASIL|COVID-19|Cardiac Arrest|Chickenpox|Chronic Pain|Fatty Liver, Alcoholic|Glabellar Reflex|Gonorrhea|Hepatitis E|Herpes Zoster|Hypotension, Orthostatic|Ischemic Stroke|Keratoconjunctivitis Sicca|Low Back Pain|Lymphoma|Neuromyelitis Optica|Non-alcoholic Fatty Liver Disease|Orthostatic Intolerance|Osteoarthritis, Knee|Pseudomonas Infections|Sexually Transmitted Diseases|Staphylococcal Infections|Surgical Wound Infection|Total Knee Arthroplasty|beta-Thalassemia
Phase 1: Acute Pain|Adenoviridae Infections|Angina Pectoris|Appendicitis|Arthritis, Infectious|Arthritis, Rheumatoid|Bacteroides Infections|Bronchiectasis|Clostridium Infections|Conjunctivitis|Coronary Disease|Gram-Positive Bacterial Infections|Healthy Volunteers|Hypertension|Keratitis|Myocardial Infarction|Other|Pelvic Infection|Pelvic Inflammatory Disease|Pneumococcal Infections|Pyelonephritis|Respiratory Syncytial Virus Infections|Spinal Diseases|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SRB2021260 | P2 |
Recruiting |
Cardiac Arrest |
2030-11-30 |
|
VAC52416BAC3001 | P3 |
Active, not recruiting |
Urinary Tract Infections |
2029-06-30 |
90% |
EVENEW | P2 |
Recruiting |
Bronchopulmonary Dysplasia |
2028-06-30 |
|
CN008-0003 | P2 |
Active, not recruiting |
Alzheimer Disease |
2027-11-16 |
12% |
RG1123550 | P2 |
Recruiting |
Lymphoma |
2027-07-31 |
83% |
2024-514903-33-00 | P2 |
Active, not recruiting |
Total Knee Arthroplasty|Osteoarthritis, Knee |
2027-06-01 |
|
CQ-001-19 | P3 |
Recruiting |
Heart Failure |
2027-04-01 |
|
MOZEG | P2 |
Not yet recruiting |
Ischemic Stroke |
2027-03-03 |
|
MK-3475-091 | P3 |
Active, not recruiting |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2027-02-02 |
|
FTP-CLIN-01 | P2 |
Recruiting |
Glabellar Reflex |
2026-01-27 |
|
GLORIA - PP-SA-003 | P2 |
Not yet recruiting |
Unknown |
2026-12-01 |
12% |
SC-3C2A | P3 |
Active, not recruiting |
Conjunctivitis, Allergic|Rhinitis, Allergic|Asthma, Allergic |
2026-09-30 |
|
PM/0059 | P3 |
Active, not recruiting |
Rhinitis, Allergic|Asthma, Allergic|Environmental Hypersensitivity|Dust mite Hypersensitivity|Conjunctivitis, Allergic |
2026-08-31 |
|
GTi1201 | P3 |
Active, not recruiting |
Emphysema|alpha 1-Antitrypsin Deficiency |
2026-08-12 |
|
FGTW2101 | P3 |
Recruiting |
Injuries/wounds Unspecified |
2026-04-30 |
|
API-EAD-2024-01 | P2 |
Withdrawn |
Unknown |
2026-03-31 |
|
2024-513828-42-00 | P2 |
Recruiting |
CADASIL |
2026-03-31 |
|
STOOD | P2 |
Recruiting |
Orthostatic Intolerance|Hypotension, Orthostatic |
2026-03-01 |
|
RNCVCT7B001 | P1 |
Enrolling by invitation |
Communicable Diseases|Pneumococcal Infections |
2026-02-01 |
12% |
IVI Hecolin S001 | P2 |
Not yet recruiting |
Hepatitis E |
2026-01-01 |
|
C4601003 | P3 |
Active, not recruiting |
Lyme Disease |
2025-12-31 |
43% |
DUO2022_01 | P2 |
Not yet recruiting |
Surgical Wound Infection |
2025-12-31 |
|
DUO2022_01 | P2 |
Recruiting |
Surgical Wound Infection|Communicable Diseases|Pseudomonas Infections|Staphylococcal Infections |
2025-12-31 |
12% |
218672 | P2 |
Active, not recruiting |
Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease |
2025-12-15 |
12% |
NVL-2024-257 | P2 |
Not yet recruiting |
Osteoarthritis, Knee |
2025-09-13 |
50% |